Global Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Industry Analysis, Size, Share, Trends and Forecast to 2018

With new product lines being launched and a strong pipeline of liver therapeutic products in development, it is expected that the field of liver therapeutics will experience huge revenue generation in the near future. In 2011, the total worth of the global liver therapeutics was USD 6,502.9 million.


Albany, NY -- (SBWIRE) -- 11/18/2015 -- The report on "Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy And Immunosuppressants) - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 – 2018" studies the performance of the different drugs class segments that are employed in liver disease therapeutics. These performance analyses have been performed based on revenue.

The report provides the market size of the liver diseases therapeutics market before carrying out a comparative analysis of the global liver disease therapeutics market based on drug class. The first two chapters offer an orientation of the general trends in the liver diseases therapeutics market.

Complete Report with TOC @

It further touches upon the various market drivers that have created numerous opportunities within this market—such as an aging population, a rise in the global prevalence of liver disease, the presence of high unmet needs in liver cancer therapeutics, and the increasing volume of vaccination in developing economies.

Furthermore, this data-driven report also offers insights into factors that could prove to be impediments to the ideal growth of this market. These include: side effects and risks associated with some of these drugs, government regulations as well as FDA approvals, and the availability of alternative treatments to patients.

The report classifies the global liver diseases therapeutics market based on the key prevailing drug class segments. These seven segments are: immunosuppressants, anti-viral drugs, immunoglobulins, chemotherapy, targeted therapy, vaccines, and corticosteroids. Going ahead, the report also provides detailed estimates and forecasts of the market size from 2012 – 2018, coupled with the compounded annual growth rate (CAGR) of each of these segments.

Inquiry on this report @

This report has been designed to offer users an unmatched competitive edge, and hence features an in-depth competitive landscape of the liver diseases therapeutics market, with complete company profiles of market players that matter. These include names such as: Astellas Pharma Inc, Novartis, Abbott Laboratories, Gilead Science Inc., Pfizer, Merck & Co., Roche, as well as Bristol-Myers Squibb, among others.

The report presents a complete analysis of the company overview, business strategies, product portfolio, recent developments, and a financial overview of these companies.
The report answers questions pertaining to the performance of liver diseases therapeutics in the worldwide market, as well as the role played by emerging markets in their performance. The report is based on in-depth and accurate primary and secondary research methodologies that have been perfected by the research team at Transparency Market Research. Our findings are further validated via analysis and consultations with C-level executives working with major companies in the liver diseases therapeutics market.

Request a Sample Copy of the Report @

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.